CO4230235A1 - Formulacion de insulina - Google Patents
Formulacion de insulinaInfo
- Publication number
- CO4230235A1 CO4230235A1 CO94035010A CO94035010A CO4230235A1 CO 4230235 A1 CO4230235 A1 CO 4230235A1 CO 94035010 A CO94035010 A CO 94035010A CO 94035010 A CO94035010 A CO 94035010A CO 4230235 A1 CO4230235 A1 CO 4230235A1
- Authority
- CO
- Colombia
- Prior art keywords
- insulin
- formulation
- zinc
- total
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
UNA FORMULACION DE INSULINA HUMANA QUE COMPRENDE UNA SUSPENSION DE CRISTALES DE INSULINA ULTRALENTE EN UNA CONCENTRACION TOTAL DE CINC EN LA FORMULA- CION DE ENTRE APROXIMADAMENTE 0.5 MILIGRAMOS Y APROXIMADAMENTE 20 MILIGRAMOS POR 100 UNIDADES DE INSULINA.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/106,106 US5534488A (en) | 1993-08-13 | 1993-08-13 | Insulin formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
CO4230235A1 true CO4230235A1 (es) | 1995-10-19 |
Family
ID=22309529
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO94035010A CO4230235A1 (es) | 1993-08-13 | 1994-08-09 | Formulacion de insulina |
Country Status (27)
Country | Link |
---|---|
US (1) | US5534488A (es) |
EP (1) | EP0646379B1 (es) |
JP (1) | JPH07149660A (es) |
KR (1) | KR950005324A (es) |
CN (1) | CN1109364A (es) |
AT (1) | ATE207761T1 (es) |
AU (1) | AU674975B2 (es) |
BR (1) | BR9403204A (es) |
CA (1) | CA2129763A1 (es) |
CO (1) | CO4230235A1 (es) |
CZ (1) | CZ193794A3 (es) |
DE (1) | DE69428860T2 (es) |
DK (1) | DK0646379T3 (es) |
ES (1) | ES2164691T3 (es) |
HU (1) | HUT67853A (es) |
IL (1) | IL110581A0 (es) |
NO (1) | NO942959L (es) |
NZ (1) | NZ264197A (es) |
PE (1) | PE14495A1 (es) |
PH (1) | PH30757A (es) |
PL (1) | PL177002B1 (es) |
PT (1) | PT646379E (es) |
RU (1) | RU2135205C1 (es) |
TW (1) | TW326394B (es) |
UA (1) | UA27874C2 (es) |
YU (1) | YU50494A (es) |
ZA (1) | ZA945939B (es) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5578238A (en) * | 1992-10-30 | 1996-11-26 | Lord Corporation | Magnetorheological materials utilizing surface-modified particles |
AR002976A1 (es) * | 1995-03-31 | 1998-05-27 | Lilly Co Eli | Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas |
US6531448B1 (en) * | 1997-12-23 | 2003-03-11 | Eli Lilly And Company | Insoluble compositions for controlling blood glucose |
EP1396272A1 (en) * | 1997-12-23 | 2004-03-10 | Eli Lilly & Company | Insoluble Insulin Compositions for Controlling Blood Glucose |
US6956021B1 (en) * | 1998-08-25 | 2005-10-18 | Advanced Inhalation Research, Inc. | Stable spray-dried protein formulations |
WO2001000675A1 (en) * | 1999-06-29 | 2001-01-04 | Eli Lilly And Company | Protamine-free insoluble acylated insulin compositions |
US7678364B2 (en) | 1999-08-25 | 2010-03-16 | Alkermes, Inc. | Particles for inhalation having sustained release properties |
EP1265630B1 (en) * | 2000-03-24 | 2006-06-07 | Genentech, Inc. | Use of insulin for the treatment of cartilagenous disorders |
EP1247283B1 (en) * | 2000-10-06 | 2006-08-16 | The Adviser - Defence Research & Development Organisation | A magneto sensitive fluid composition and a process for preparation thereof |
US6875368B2 (en) * | 2000-11-29 | 2005-04-05 | The Adviser Defence Research And Development Organisation, Ministry Of Defence, Government Of India | Magnetorheological fluid composition and a process for preparation thereof |
IL156435A0 (en) * | 2001-02-09 | 2004-01-04 | Genentech Inc | Crystallization of igf-1 |
DE10114178A1 (de) | 2001-03-23 | 2002-10-10 | Aventis Pharma Gmbh | Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität |
AU2003223158B2 (en) | 2002-01-09 | 2008-01-17 | Emisphere Technologies, Inc. | Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoate |
DE10227232A1 (de) * | 2002-06-18 | 2004-01-15 | Aventis Pharma Deutschland Gmbh | Saure Insulinzubereitungen mit verbesserter Stabilität |
US7658721B2 (en) * | 2004-01-16 | 2010-02-09 | Biodel Inc. | Sublingual drug delivery device |
US20080248999A1 (en) * | 2007-04-04 | 2008-10-09 | Biodel Inc. | Amylin formulations |
US20080085298A1 (en) * | 2004-03-12 | 2008-04-10 | Biodel, Inc. | Rapid Mucosal Gel or Film Insulin Compositions |
US20080096800A1 (en) * | 2004-03-12 | 2008-04-24 | Biodel, Inc. | Rapid mucosal gel or film insulin compositions |
ES2328048T3 (es) * | 2004-03-12 | 2009-11-06 | Biodel, Inc. | Composiciones de insulina con absorcion mejorada. |
US20080090753A1 (en) | 2004-03-12 | 2008-04-17 | Biodel, Inc. | Rapid Acting Injectable Insulin Compositions |
ES2879880T3 (es) | 2004-05-06 | 2021-11-23 | Novo Nordisk North America Operations As | Formas polimórficas cristalinas del n-[8-(2-hidroxibenzoil)amino]caprilato monosódico |
NZ551241A (en) * | 2004-05-14 | 2010-08-27 | Emisphere Tech Inc | Aryl ketone compounds and compositions for delivering active agents |
UA91512C2 (ru) * | 2004-07-19 | 2010-08-10 | Биокон Лимитед | Коньюгати олигомеров инсулина, их композиция (варианты) и применение |
AU2005271526B2 (en) | 2004-08-03 | 2011-12-08 | Emisphere Technologies, Inc. | Antidiabetic oral insulin-biguanide combination |
US20060078622A1 (en) * | 2004-08-13 | 2006-04-13 | Emisphere Technologies, Inc. | Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent |
US8084420B2 (en) * | 2005-09-29 | 2011-12-27 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
US7713929B2 (en) * | 2006-04-12 | 2010-05-11 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
WO2007121256A2 (en) * | 2006-04-12 | 2007-10-25 | Biodel, Inc. | Rapid acting and long acting insulin combination formulations |
CA2681158C (en) | 2007-03-13 | 2018-09-18 | Nutrition 21, Inc. | Methods and compositions for the sustained release of chromium |
WO2009002867A2 (en) | 2007-06-26 | 2008-12-31 | Nutrition 21, Inc. | Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement |
UA114700C2 (uk) | 2007-10-16 | 2017-07-25 | Біокон Лімітед | Тверда фармацевтична форма для перорального застосування та процес її виготовлення |
CA2711561A1 (en) * | 2008-01-04 | 2009-07-16 | Biodel, Inc. | Insulin formulations for insulin release as a function of tissue glucose levels |
CA3016451A1 (en) | 2008-10-17 | 2010-04-22 | Sanofi-Aventis Deutschland Gmbh | Combination of an insulin and a glp-1 agonist |
US9060927B2 (en) * | 2009-03-03 | 2015-06-23 | Biodel Inc. | Insulin formulations for rapid uptake |
RU2537239C2 (ru) | 2009-11-13 | 2014-12-27 | Санофи-Авентис Дойчланд Гмбх | Фармацевтическая композиция, включающая агонист glp-1, инсулин и метионин |
KR101772372B1 (ko) | 2009-11-13 | 2017-08-29 | 사노피-아벤티스 도이칠란트 게엠베하 | Glp-1 효능제 및 메티오닌을 포함하는 약제학적 조성물 |
BR112012020481A2 (pt) * | 2010-02-22 | 2017-01-10 | Univ Case Western Reserve | método para tratar um paciente, o método compreendendo administrar uma formulação farmacêutica contendo uma quantidade fisiologicamente efetiva de um análogo de insulina ou um sal fisiologicamente. |
HUE031181T2 (en) | 2010-08-30 | 2017-06-28 | Sanofi Aventis Deutschland | Use of AVE0010 for the manufacture of a medicament for the treatment of type 2 diabetes |
WO2012119007A1 (en) | 2011-03-01 | 2012-09-07 | N21 Acquisition Holding, Llc | Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
HRP20230470T1 (hr) | 2014-12-12 | 2023-07-21 | Sanofi-Aventis Deutschland Gmbh | Formulacija fiksnog omjera inzulin glargin/liksisenatid |
TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患治療 |
TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患之治療 |
EP3413900A1 (en) | 2016-02-11 | 2018-12-19 | Nutrition 21, LLC | Chromium containing compositions for improving health and fitness |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2626228A (en) * | 1945-05-17 | 1953-01-20 | Novo Terapeutisk Labor As | Method of producing crystalline insulin |
US2882202A (en) * | 1950-04-05 | 1959-04-14 | Novo Terapeutisk Labor As | Insulin crystal preparations and methods of producing them |
US2882203A (en) * | 1951-06-26 | 1959-04-14 | Novo Terapeutisk Labor As | Injectable insulin preparation with protracted effect |
US2849370A (en) * | 1953-06-04 | 1958-08-26 | Novo Terapeutisk Labortorium A | Injectable insulin preparations with protracted effect and process of producing same |
US3102077A (en) * | 1953-08-19 | 1963-08-27 | Christensen Henry Marinus | Preparation of insulin containing 2.75 to 8 percent zinc content |
US2819999A (en) * | 1953-11-13 | 1958-01-14 | Novo Terapeutisk Labor As | Process for crystallization of insulin using freeze dried insulin as seeding material |
US2799622A (en) * | 1953-11-14 | 1957-07-16 | Novo Terapeutisk Labor As | Process of producing insulin crystals of substantially uniform size and compositions thereof |
US3060093A (en) * | 1957-07-18 | 1962-10-23 | Nordisk Insulinlab | Slowly acting insulin preparation in crystalline form and method of preparation |
DE2933946A1 (de) * | 1979-08-22 | 1981-03-12 | Hoechst Ag, 6000 Frankfurt | Insulinkristallsuspension und verfahren zu ihrer herstellung. |
FI78616C (fi) * | 1982-02-05 | 1989-09-11 | Novo Industri As | Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt. |
PH23446A (en) * | 1986-10-20 | 1989-08-07 | Novo Industri As | Peptide preparations |
DE3827533A1 (de) * | 1988-08-13 | 1990-02-15 | Hoechst Ag | Pharmazeutische zubereitung zur behandlung des diabetes mellitus |
-
1993
- 1993-08-13 US US08/106,106 patent/US5534488A/en not_active Expired - Fee Related
-
1994
- 1994-08-04 HU HU9402287A patent/HUT67853A/hu unknown
- 1994-08-08 NZ NZ264197A patent/NZ264197A/en unknown
- 1994-08-08 BR BR9403204A patent/BR9403204A/pt not_active Application Discontinuation
- 1994-08-08 ZA ZA945939A patent/ZA945939B/xx unknown
- 1994-08-08 IL IL11058194A patent/IL110581A0/xx not_active IP Right Cessation
- 1994-08-08 PE PE1994248043A patent/PE14495A1/es not_active Application Discontinuation
- 1994-08-09 TW TW083107259A patent/TW326394B/zh active
- 1994-08-09 DK DK94305883T patent/DK0646379T3/da active
- 1994-08-09 CA CA002129763A patent/CA2129763A1/en not_active Abandoned
- 1994-08-09 KR KR1019940019550A patent/KR950005324A/ko active IP Right Grant
- 1994-08-09 CO CO94035010A patent/CO4230235A1/es unknown
- 1994-08-09 AT AT94305883T patent/ATE207761T1/de not_active IP Right Cessation
- 1994-08-09 DE DE69428860T patent/DE69428860T2/de not_active Expired - Fee Related
- 1994-08-09 PL PL94304600A patent/PL177002B1/pl unknown
- 1994-08-09 PH PH48764A patent/PH30757A/en unknown
- 1994-08-09 UA UA94085696A patent/UA27874C2/uk unknown
- 1994-08-09 ES ES94305883T patent/ES2164691T3/es not_active Expired - Lifetime
- 1994-08-09 EP EP94305883A patent/EP0646379B1/en not_active Expired - Lifetime
- 1994-08-09 NO NO942959A patent/NO942959L/no not_active Application Discontinuation
- 1994-08-09 PT PT94305883T patent/PT646379E/pt unknown
- 1994-08-09 RU RU94028671A patent/RU2135205C1/ru active
- 1994-08-10 JP JP6188204A patent/JPH07149660A/ja not_active Withdrawn
- 1994-08-10 CN CN94109082A patent/CN1109364A/zh active Pending
- 1994-08-10 YU YU50494A patent/YU50494A/sh unknown
- 1994-08-10 CZ CZ941937A patent/CZ193794A3/cs unknown
- 1994-08-12 AU AU70247/94A patent/AU674975B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
NO942959D0 (no) | 1994-08-09 |
US5534488A (en) | 1996-07-09 |
IL110581A0 (en) | 1994-11-11 |
NZ264197A (en) | 1997-01-29 |
KR950005324A (ko) | 1995-03-20 |
AU674975B2 (en) | 1997-01-16 |
RU2135205C1 (ru) | 1999-08-27 |
EP0646379B1 (en) | 2001-10-31 |
ATE207761T1 (de) | 2001-11-15 |
PL304600A1 (en) | 1995-02-20 |
DK0646379T3 (da) | 2001-12-03 |
CN1109364A (zh) | 1995-10-04 |
PL177002B1 (pl) | 1999-09-30 |
CA2129763A1 (en) | 1995-02-14 |
ZA945939B (en) | 1996-02-08 |
PT646379E (pt) | 2002-03-28 |
JPH07149660A (ja) | 1995-06-13 |
PH30757A (en) | 1997-10-17 |
BR9403204A (pt) | 1995-04-18 |
AU7024794A (en) | 1995-02-23 |
NO942959L (no) | 1995-02-14 |
DE69428860T2 (de) | 2002-05-02 |
HU9402287D0 (en) | 1994-09-28 |
EP0646379A1 (en) | 1995-04-05 |
ES2164691T3 (es) | 2002-03-01 |
YU50494A (sh) | 1997-01-08 |
CZ193794A3 (en) | 1995-03-15 |
UA27874C2 (uk) | 2000-10-16 |
PE14495A1 (es) | 1995-06-02 |
TW326394B (en) | 1998-02-11 |
DE69428860D1 (de) | 2001-12-06 |
HUT67853A (en) | 1995-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2164691T3 (es) | Formulacion de insulina. | |
AU610636B2 (en) | Stabilised human protein preparations | |
ES8101382A1 (es) | Un procedimiento para la obtencion de un aglutinante para los tejidos a base de proteinas humanas o animales | |
NO912281L (no) | Isoformer av erythropoietin. | |
CA2015186A1 (en) | Nutrient composition | |
NZ228710A (en) | Modified "echistatin" and anti-clotting pharmaceutical composition | |
AU2670495A (en) | Ifn-beta liquid formulations | |
AU8188087A (en) | Variants of hirudin, their use and their preparation | |
EP0511903A3 (en) | Conjugate of calcitonin and polyethylene glycol | |
AU624079B2 (en) | Novel fluorinated derivatives of amino acids usable more particularly as surfactants or cosurfactants and preparations for biomedical use incorporating these derivatives | |
AU5707090A (en) | Hair treatment composition | |
AU6406590A (en) | Porcine lactoferrin amino acid and cdna sequence | |
AU8375891A (en) | Antioxidant system based on a basic amino acid in combination with a tocopherol or derivative thereof and a nonthiolated polypeptide, and compositions containing the same | |
MD1714G2 (ro) | Compoziţie terapeutică în formă de sirop, conţinând N-acetilcisteină | |
EP0508435A3 (en) | Pharmaceutical composition of stabilized (leu 13)-motilin-hse | |
CA2153071A1 (en) | Derivatized calcitonins | |
GR3007486T3 (es) | ||
ATE262307T1 (de) | Verwendung von goldlegierungen für konstruktionselemente in der dentaltechnik | |
EP0300741A3 (en) | Human thymopoietin | |
EP0292302A3 (en) | Human splenin | |
HU201445B (en) | Herbicide composition containing sulfonyl-urea derivative as active component and glycinamide derivative as antidotum | |
TH17521A (th) | สูตรผสมอินซูลิน | |
AU6985287A (en) | 1,2,3,4-tetrahydro-6-substituted-4-aryl(or heterocyclo)-3- {(substituted amino)carbonyl}-2-thioxo(or oxo)-5-pyrimidine -carboxylic acids and esters |